Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
PHASE2
This study aims to evaluate the immunogenicity, by means of cell mediated i...
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age
PHASE2
The present study is designed to confirm the safety and immunogenicity of t...
Status
Completed
Location
Antwerp University Centre for the Evaluation of Vaccination